A recent report revealed that trebananib failed to improve the health of the patients who suffers from ovarian cancer. Trebanaib is the last phase medicine for the cure of ovarian cancer patients.
Recently, experts performed a trial on a patient in order to check the performance of this new drug. Unfortunately, the result demonstrated that the patient merely lived a month longer than the expectations of doctors. It signifies that the drug is not that much effective for the cancer patients.
Also read: Trump's next big idea on health care